Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04610463
Other study ID # MEASURE-PFO
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 25, 2020
Est. completion date December 2023

Study information

Verified date October 2020
Source University Hospital Hradec Kralove
Contact Josef Štásek
Phone +420495832248
Email josef.stasek@fnhk.cz
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the project is to identify new risk indicators of PFO. The evaluation of the R-L shunt is based on the newly developed precise measurement technique. Moreover, this measurement of R-L shunt is feasible in a case when R-L shunt is present only intermittently. Multicentric study with 150 patients.


Description:

The aim of the proposed project is to identify new risk indicators of PFO. The evaluation of the R-L shunt is based on the newly developed precise measurement technique. Moreover, this measurement of R-L shunt is feasible in a case when R-L shunt is present only intermittently. Detection and quantification of R-L shunt will be realized by the original INNTHERM® ® system (Innova Medical s.r.o., Velká Dobrá). This system is based on the principle of thermodilution. The basic assumption of our study is the hypothesis, that the size of the R-L shunt (and especially its maximum size during intra-abdominal pressure increase) is a risk factor for the development of paradoxical embolism (from pulmonary to systemic circulation). The most critical consequence of paradoxical embolism is the development of ischemic stroke. Such measurement with an unequivocal accuracy has never been done so far, due a lack of technology precise enough. Precise quantification of R-L shunt will allow a more accurate prediction of high-risk patients, especially after correlation with commonly used methods. PFO is now an indication for implantation of percutaneous occlusion device only in case of secondary prevention of stroke, i.e. in a group of patients who have had an ischemic stroke. Prospectively, precise and better identification of a risk group of these patients could lead to cost reduction of treatment. This cost reduction is crucial for young working-age patients who can be treated before a major irreversible brain injury occurs. A parameter applicable in primary prevention saves the cost of ischemic stroke treatment and other systemic embolism; additionally it will contribute to cost reduction during aftercare treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Male and female patients aged =18 and < 60 years 2. Cryptogenic stroke or Systemic embolization due to paradoxical embolization via Patent Foramen Ovale 3. The patient indicated for occlusion of PFO with catheter occluder Exclusion Criteria: 1. Inability to perform spiroergometry 2. Inability to perform Transesophageal echocardiography (TEE) 3. Inability to perform proper Valsalva maneuver 4. Inability to understand and/or signed informed consent form 5. Contraindication of Patent Foramen Ovale occlusion by any medical reason or patient refusal

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Cardiac flow measurement
Catheterized hemodynamics evaluation - a measurement of systemic flow and pulmonary flow, R-L shunt, L-R shunt using the INNTHERM® system, prior to PFO closure using a common PFO-occluder (within one catheterization intervention).

Locations

Country Name City State
Czechia Fakultní nemocnice Brno Brno
Czechia I. interní kardioangiologická klinika, Fakultní nemocnice Hradec Králové Hradec Králové
Czechia Fakultní nemocnice Ostrava Ostrava
Czechia Nemocnice Na Homolce Praga
Czechia Institut klinické a experimentální medicíny (IKEM) Praha
Czechia Všeobecná fakultní nemocnice v Praze Praha

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Hradec Kralove

Country where clinical trial is conducted

Czechia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quantification of R-L shunt namely Right-to Left shunt will be measured and quantified using by the novel system for measurement of Cardiac flow- Inntherm. We will obtain these hemodynamics parameters: Systemic blood flow (SBF) pulmonary blood (PBF) Cardiac index (CI), ration of QP/QS. Right to left shunt will be quantified in liters per minutes as well as % of SBF and % of PBF.
We will evaluate R-L shunt in normal conditions as well as after inducible Valsalva maneuver.
Each patient will fill EQ-5D at the beginning of the study and Then 24 weeks after PFO closure.
Up to 24 weeks
Primary Transesophageal Echocardiography examination before Patent foramen ovale closure To evaluate the morphology of atrial septum Up to 24 weeks (Prior subject's Patent foramen ovale closure)
Primary Evaluation of the severity of Right-Left shunt and comparison with atrial septal morphology Is there a significant correlation between atrial septal morphology and the level of severity of cardiac shunt as a predictive factor for systemic embolism Up to 24 weeks
Primary Spiroergometric examination with the measurement of VO2max Detection of possible desaturation using the spiroergometric examination 6 months after Patent foramen ovale closure by means of a Patent foramen ovale occluder
Primary Spiroergometric examination with the measurement of SpO2 Detection of possible desaturation using the spiroergometric examination 6 months after Patent foramen ovale closure by means of a Patent foramen ovale occluder
Primary Transesophageal Echocardiography routine examination after 6 months after Patent foramen ovale closure To evaluate results 6 months after Patent foramen ovale closure by means of a Patent foramen ovale occluder with a routine examination of Transesophageal Echocardiography Up to 24 weeks
Primary Influence of significant R-L shunt on exercise tolerance and quality of life of the patient To judge if the closure of Patent foramen ovale especially by the group of patients with significant R-L shunt may influence exercise tolerance and quality of patient life. Precise results of quantification of R-L Shunt will significantly correlated with a possible complications of PFO - systemic embolization, desaturation syndromes. Up to 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Completed NCT02882815 - Post Market Clinical Follow-up Study of IrisFITTM PFO (Patent Foramen Ovale) Occluder N/A
Completed NCT04604015 - RoBotic TCD Ultrasound BubbLe Study Compared to Transthoracic Echocardiography for Detection of Right to Left Shunt N/A
Active, not recruiting NCT04950192 - Philips Intracardiac Echocardiography (ICE) Clinical Registry
Not yet recruiting NCT04549272 - Assessment of Early Vascular Damage With Advanced Neuroimaging in Patient With Patent Foramen Ovale
Completed NCT02621528 - Lifetech CeraFlex™ Post-Market Surveillance Study N/A
Terminated NCT01018355 - The Effect of Device Closure of Patent Foramen Ovale in Elderly Patients With Crytogenic Stoke/TCI N/A
Completed NCT00831259 - Risk of Stroke in Pulmonary Embolism With a Patent Foramen Ovale (PFO) N/A
Not yet recruiting NCT05360771 - Study on the Safety and Effectiveness of the SnowyTM PFO Closure System N/A
Recruiting NCT05546320 - Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale Phase 4
Recruiting NCT05561660 - COMParison of the EffecT of dEvice Closure in Alleviating Migraine With PFO (COMPETE-2) Phase 4
Completed NCT03904277 - Does Patent Foramen Ovale Size Matter in Men and Women
Recruiting NCT06120270 - CeraFlex PFO Closure System PMCF Study
Terminated NCT01773252 - Right to Left Cardiac Shunt Detection Phase 3
Completed NCT01216423 - Pulmonary Embolism and Stroke in Patient With Patent Foramen Ovale N/A
Completed NCT03377465 - Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis N/A
Active, not recruiting NCT04738071 - International Multicenter Patent foRamen OVale & strokE (IMPROVE) Registry
Not yet recruiting NCT06413147 - Long-term Procedural and Device Related Complications of PFO Closure
Not yet recruiting NCT06344494 - Cardiac Interventional ICE Imaging Trial N/A
Withdrawn NCT02378623 - Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli Phase 2